MedPath

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

Phase 4
Conditions
HIV Infections
Lipodystrophy
Registration Number
NCT00426296
Lead Sponsor
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
Brief Summary

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Detailed Description

Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA \<50 copies/mL at entry

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
  • Viral load <50 copies/ml
Exclusion Criteria
  • Viral load >50 copies/ml
  • Having taken more than one antiretroviral regimen

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Whitman-Walker Clinic

🇺🇸

Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath